High Expression of CDK1 and NDC80 Predicts Poor Prognosis of Bladder Cancer

TL;DR

This study identifies CDK1 and NDC80 as potential biomarkers for bladder cancer prognosis by analyzing gene expression profiles and pathway enrichment, revealing their association with poor outcomes and suggesting new avenues for diagnosis and research.

Contribution

The paper introduces CDK1 and NDC80 as novel biomarkers for bladder cancer prognosis based on gene expression analysis and pathway enrichment, filling a gap in current research.

Findings

CDK1 and NDC80 are overexpressed in bladder cancer tissues.

High expression of these genes predicts poor prognosis.

Pathway analysis links these genes to cancer-related pathways.

Abstract

Background: Bladder cancer is the 10th most common cancer worldwide, and its prevalence is increasing, especially in developing countries. Objective: In the present study, we employed gene expression profiles from the GSE163209 data set in the GEO database to identify potential molecular and genetic markers in BC patients. Methods: The data set comprised 217 samples, with 113 stage Ta tumor tissue samples and 104 stage T1 tumor tissue samples. The top 766 genes were chosen. P.value<0.0001 and |logFC|=1 was used to change the cutoff criteria for defining DEGs. Moreover, the MCODE plugin and cytoHubba plugin were employed to produce a module and detect 20 hub genes in these DEGs. We used GO and KEGG pathway enrichment analyses to get a better understanding of these DEGs. Results: The KEGG pathway enrichment results indicated that the top genes were mainly involved: Systemic lupus erythematosus, Alcoholism, and Viral carcinogenesis. SLE activation in the renal glomeruli could explain the connection between this disease's route and bladder cancer, and according to our results and previous researches, heavy alcohol intake can increase the risk of BC in males and particular populations. Conclusion: According to our hub genes, we can consider CDK1 and NDC80 as bladder cancer biomarkers. Not much research has been done on the effect of this gene on bladder cancer.